Associations Between HLA-DRB1*0102, HLA-B*5801, and Hepatotoxicity During Initiation of Nevirapine-Containing Regimens in South Africa
Authors:
- 1 February 2013
- journal article
- letter
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 62 (2) , e55-e57
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descentAIDS, 2011
- HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patientsPharmacogenetics and Genomics, 2009
- HLA-Cw8 primarily associated with hypersensitivity to nevirapineAIDS, 2007
- Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group CollaborationClinical Infectious Diseases, 2006
- HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patientsAIDS, 2006
- Severe Hepatotoxicity Associated with Nevirapine Use in HIV‐Infected SubjectsThe Journal of Infectious Diseases, 2005
- HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinolProceedings of the National Academy of Sciences, 2005
- Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell countsAIDS, 2005
- Association between presence of HLA-B*5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirThe Lancet, 2002